LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Listă Acțiuni・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Închisă

13.94 8.48

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

12.79

Maxim

13.94

Indicatori cheie
By Trading Economics
Venit	-6.4M -20M
Vânzări	-807K 71M
EPS	-0.13
Marjă de profit	-28.24
Angajați	624
EBITDA	-7.9M -14M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+55.63% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-282M 2B
Deschiderea anterioară	5.46
Închiderea anterioară	13.94

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

8.81 / 10.18 Suport & Rezistență

Adaptive Biotechnologies Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

20 mai 2026, 23:31 UTC

Acțiuni populare

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 mai 2026, 22:52 UTC

Principalele dinamici ale pieței

Osisko Shares Fall on Planned Convertible Notes Offering

20 mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 mai 2026, 23:44 UTC

Câștiguri

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 mai 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 mai 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 mai 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20 mai 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 mai 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 mai 2026, 23:14 UTC

Câștiguri

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 mai 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 mai 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 mai 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20 mai 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20 mai 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 mai 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 mai 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 mai 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 mai 2026, 22:10 UTC

Câștiguri

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 mai 2026, 22:00 UTC

Câștiguri

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 mai 2026, 21:38 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 mai 2026, 21:27 UTC

Câștiguri

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 mai 2026, 21:20 UTC

Câștiguri

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 mai 2026, 21:19 UTC

Câștiguri

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 mai 2026, 21:18 UTC

Câștiguri

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 mai 2026, 21:17 UTC

Câștiguri

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 mai 2026, 21:17 UTC

Câștiguri

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 mai 2026, 21:17 UTC

Câștiguri

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 mai 2026, 21:16 UTC

Câștiguri

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Comparație

Modificare preț

Adaptive Biotechnologies Corp Așteptări

Obiectiv de preț

By TipRanks

55.63% sus

Prognoză pe 12 luni

Medie 20.17 USD 55.63%

Maxim 22 USD

Minim 18 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAdaptive Biotechnologies Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Adaptive Biotechnologies Corp - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

8.81 / 10.18Suport & Rezistență

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.